202 related articles for article (PubMed ID: 22547012)
41. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
42. Upregulated OCT3 has the potential to improve the survival of colorectal cancer patients treated with (m)FOLFOX6 adjuvant chemotherapy.
Gu J; Dong D; Long E; Tang S; Feng S; Li T; Wang L; Jiang X
Int J Colorectal Dis; 2019 Dec; 34(12):2151-2159. PubMed ID: 31732877
[TBL] [Abstract][Full Text] [Related]
43. Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients.
Sugimoto S; Katano K; Kanazawa A; Yoshimura H; Kidani A; Takeda H; Makino M; Ozaki N; Tanaka T; Ikeguchi M
J Exp Clin Cancer Res; 2009 Aug; 28(1):109. PubMed ID: 19664225
[TBL] [Abstract][Full Text] [Related]
44. Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.
Clin Colorectal Cancer; 2002 Aug; 2(2):78-80. PubMed ID: 12453320
[No Abstract] [Full Text] [Related]
45. [Two cases of advanced colorectal cancer which demonstrated the reversibility of oxaliplatin-mediated increase in splenic volume].
Motoori S; Kawase T; Nishimura H; Hosokawa Y; Konno T; Hanai C; Kitagawa N; Saisho H; Furuse J
Gan To Kagaku Ryoho; 2011 Apr; 38(4):677-80. PubMed ID: 21499004
[TBL] [Abstract][Full Text] [Related]
46. Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.
Cao Y; Chang Q; Zhang W; Ornatsky O; Hedley D; Chen EX
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1195-1200. PubMed ID: 31520102
[TBL] [Abstract][Full Text] [Related]
47. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx
Glimelius B; Manojlovic N; Pfeiffer P; Mosidze B; Kurteva G; Karlberg M; Mahalingam D; Buhl Jensen P; Kowalski J; Bengtson M; Nittve M; Näsström J
Acta Oncol; 2018 Mar; 57(3):393-402. PubMed ID: 29140155
[TBL] [Abstract][Full Text] [Related]
48. Oxaliplatin treatment and peripheral nerve damage in cancer patients: A Polish cohort study.
Banach M; Zygulska AL; Krzemieniecki K
J Cancer Res Ther; 2018; 14(5):1010-1013. PubMed ID: 30197340
[TBL] [Abstract][Full Text] [Related]
49. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Infante JR; Reid TR; Cohn AL; Edenfield WJ; Cescon TP; Hamm JT; Malik IA; Rado TA; McGee PJ; Richards DA; Tarazi J; Rosbrook B; Kim S; Cartwright TH
Cancer; 2013 Jul; 119(14):2555-63. PubMed ID: 23605883
[TBL] [Abstract][Full Text] [Related]
50. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW
Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359
[TBL] [Abstract][Full Text] [Related]
51. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Kobayashi M; Sato R; Komura T; Ichikawa H; Hirashima T; Otake S; Akazawa N; Yazawa T; Abe T; Okada T; Kakita T; Oikawa M; Tsuchiya T
Int J Clin Oncol; 2020 Oct; 25(10):1814-1821. PubMed ID: 32594273
[TBL] [Abstract][Full Text] [Related]
52. Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
Nakayama G; Kodera Y; Yokoyama H; Okuda N; Watanabe T; Tanaka C; Iwata N; Ohashi N; Koike M; Fujiwara M; Nakao A
Int J Clin Oncol; 2011 Oct; 16(5):506-11. PubMed ID: 21431344
[TBL] [Abstract][Full Text] [Related]
53. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
Kanai M; Kawaguchi T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Ishigure K; Hasegawa J; Munemoto Y; Matsui T; Takagane A; Ishikawa H; Matsumoto S; Sakamoto J; Saji S; Yoshino T; Ohtsu A; Watanabe T; Matsuda F
Ann Oncol; 2016 Jun; 27(6):1143-1148. PubMed ID: 27069012
[TBL] [Abstract][Full Text] [Related]
54. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
Lubner SJ; Loconte NK; Holen KD; Schelman W; Thomas JP; Jumonville A; Eickhoff JC; Seo S; Mulkerin DL
Clin Colorectal Cancer; 2010 Jul; 9(3):157-61. PubMed ID: 20643620
[TBL] [Abstract][Full Text] [Related]
55. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer.
Kern W; Beckert B; Lang N; Stemmler J; Beykirch M; Stein J; Goecke E; Waggershauser T; Braess J; Schalhorn A; Hiddemann W
Ann Oncol; 2001 May; 12(5):599-603. PubMed ID: 11432616
[TBL] [Abstract][Full Text] [Related]
56. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Yoshino T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Matsui T; Ishigure K; Hasegawa J; Inoue K; Munemoto Y; Takagane A; Ishikawa H; Ishida H; Ogata Y; Oba K; Goto K; Sakamoto J; Maehara Y; Ohtsu A
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1269-1277. PubMed ID: 31549217
[TBL] [Abstract][Full Text] [Related]
57. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
[TBL] [Abstract][Full Text] [Related]
58. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
[TBL] [Abstract][Full Text] [Related]
59. Oxaliplatin: a welcome addition to our therapeutic armamentarium.
Chu E
Clin Colorectal Cancer; 2002 Aug; 2(2):72. PubMed ID: 12453318
[No Abstract] [Full Text] [Related]
60. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer.
Vedat Bayoglu I; Yildiz I; Varol U; Cokmert S; Kucukzeybek Y; Alacacioglu A; Demir L; Dirican A; Akyol M; Yildiz Y; Oktay Tarhan M
J BUON; 2015; 20(2):460-7. PubMed ID: 26011336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
